Show simple item record

Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry

dc.contributor.author Grabowski, HG
dc.contributor.author Vernon, JM
dc.contributor.author Thomas, LG
dc.date.accessioned 2010-06-28T19:40:31Z
dc.date.available 2010-06-28T19:40:31Z
dc.date.issued 1978
dc.identifier.uri https://hdl.handle.net/10161/2648
dc.description.abstract INNOVATION in the U.S. ethical drug industry in recent years has been characterized by a number of adverse developments. In particular, there has been a sharp decline in the rate of new product introductions and the incentive for engaging in research and development (R & D) activity has been negatively influenced by rapid increases in the costs and risks of developing new products. While there is little debate about the existence of these adverse trends, there is considerable controversy about the factors producing them. Briefly, we list below five hypotheses that have been discussed as explanations for the declining rate of innovation.`
dc.format.extent 3171687 bytes
dc.format.mimetype application/pdf
dc.language.iso en_US
dc.publisher University of Chicago Press
dc.subject Pharmaceutical Industry
dc.subject innovation
dc.subject regulation
dc.title Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry
dc.type Journal article
duke.contributor.id Grabowski, HG|0099498


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record